Abrégé

The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to compositions and methods for treating myotonic dystrophy.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 35/761 - Adénovirus

Abrégé

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The invention relates to a device (5) for determining the quantities of filling liquid and vasopressor to be administered to a patient by means of respectively a first dispenser (3) and a second dispenser (4), characterised in that the device (5) is designed to determine a quantity of filling liquid and a quantity of vasopressor, on the basis of the previously measured blood pressure of a patient, such that said quantities depend on the ratio between quantities of filling liquid and vasopressor that have already been administered over a given period.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/029 - Mesure du débit de sang à la sortie du cœur, p. ex. volume éjecté par minute
• A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes

Abrégé

The present invention relates to improved constructs comprising the short and long Rod- Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

A method of analyzing a visual field of an individual comprises the following steps: - measuring (S4) a first visual field (VF1) of said individual for a first set of oculo-postural parameters of said individual when said individual performs a first task; - measuring (S6) at least one additional visual field (VFi) of said individual for one additional set of said oculo-postural parameters of said individual when said individual performs an additional task; - determining (S8) a functional visual space based on said first visual field (VF1) and said at least one additional visual field (VFi), said functional visual space being an envelope of said first visual field and said at least one additional visual field. The additional task differs from said first task and/or said additional set of oculo-postural parameters differs from said first set of oculo-postural parameters. A corresponding ophthalmic lens is also proposed.

Classes IPC  ?

• A61B 3/024 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour la détermination du champ de vision, p. ex. périmètres

Abrégé

The present invention relates to novel phytopharmaceutical compounds, in particular to elicitors of natural plant defenses, to compositions comprising such compounds, and to uses thereof. The invention also relates in particular to a process for producing the novel phytopharmaceutical compounds.

Classes IPC  ?

• A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
• A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits

Abrégé

An electromagnetic sensing device (400) for detecting magnetic nanoparticles, comprising: a reference microfiuidic reservoir (RR) to receive a reference substance with magnetic nanoparticles; an analyte microfiuidic reservoir (AR) to receive an analyte and magnetic nanoparticles; a first excitation magnetic coil (HF1) to subject the reference microfiuidic reservoir (RR) to an alternating magnetic field at a first frequency; a second excitation magnetic coil (HF2) to subject the analyte microfiuidic reservoir (AR) to an alternating magnetic field at the first frequency; a third excitation magnetic coil (BFl) to subject the reference microfiuidic reservoir (RR) to an alternating magnetic field at a second frequency distinct from the first frequency; a fourth excitation magnetic coil (BF2) to subject the analyte microfiuidic reservoir (AR) to an alternating magnetic field at the second frequency; a first detection magnetic coil (D1) to detect a response magnetic field of the magnetic nanoparticles in the reference microfiuidic reservoir (RR); a second detection magnetic coil (D2) to detect a response magnetic field of the magnetic nanoparticles in the analyte microfiuidic reservoir (AR). The electromagnetic sensing device is structured according to a plurality of superimposed layers (L1, L2, L3, L4, L5), comprising at least three coil layers (L2, L3, L4, L5) and a reservoir layer (L1).

Classes IPC  ?

• G01N 27/74 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables magnétiques des fluides

Abrégé

LMNALMNALMNA-related dilated cardiomyopathies.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The invention relates to a process for manufacturing at least one implant for focal electrical stimulation of a nervous structure, said implant being of the type including in a supporting structure a network of cavities at the bottom of which are placed microelectrodes, the cavities being bounded by walls erected and located around the microelectrodes, the supporting structure being produced beforehand by implementing the following steps: deposition and etching, in a planar manner, on an insulating substrate, of electrical contacts, of electrical tracks and of microelectrodes, first tracks electrically connecting the microelectrodes and the electrical contacts, second electrical tracks being electrically connected to a ground.

Classes IPC  ?

• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61N 1/02 - ÉlectrothérapieCircuits à cet effet Parties constitutives
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
• H01B 5/14 - Conducteurs ou corps conducteurs non isolés caractérisés par la forme comprenant des couches ou pellicules conductrices sur supports isolants
• H01B 13/00 - Appareils ou procédés spécialement adaptés à la fabrication de conducteurs ou câbles
• H05K 3/06 - Élimination du matériau conducteur par voie chimique ou électrolytique, p. ex. par le procédé de photo-décapage
• H05K 3/46 - Fabrication de circuits multi-couches

Abrégé

The invention relates to a method for characterising bone, the method comprising the steps of receiving (102) ultrasonic wave echo signals transmitted into a body, determining (104) a speed of sound in the body's non-bone biological tissue, locating (106) a first demarcation curve between non-bone biological tissue and bone in an image of the body constructed during said determining step, and determining (108) a speed of sound in bone. The steps of determining speed include constructing images from the signals, and a metric calculation indicative of a focus quality in the constructed images.

Classes IPC  ?

• A61B 8/08 - Applications cliniques

Abrégé

A coated metallic substrate and fabrication method The present invention relates to a coated metallic substrate comprising, at least; one layer of oxides, such layer being directly topped by an intermediate coating layer comprising Fe, Ni, Cr and Ti wherein the amount of Ti is above or equal to 5 wt.% and wherein the following equation is satisfied: 8 wt.% < Cr +Ti < 40 wt.%, the balance being Fe and Ni, such intermediate coating layer being directly topped by a coating layer being an anticorrosion metallic coating.

Classes IPC  ?

• C23C 28/00 - Revêtement pour obtenir au moins deux couches superposées, soit par des procédés non prévus dans un seul des groupes principaux , soit par des combinaisons de procédés prévus dans les sous-classes et
• B32B 15/00 - Produits stratifiés composés essentiellement de métal
• C25D 5/36 - Prétraitement des surfaces métalliques à revêtir de métaux par voie électrolytique de fer ou d'acier
• C23C 14/02 - Pré-traitement du matériau à revêtir
• C23C 14/16 - Matériau métallique, bore ou silicium sur des substrats métalliques, en bore ou en silicium
• C23C 14/35 - Pulvérisation cathodique par application d'un champ magnétique, p. ex. pulvérisation au moyen d'un magnétron
• C22C 38/00 - Alliages ferreux, p. ex. aciers alliés

Abrégé

An energy converter (1) comprising at least one electrochemical cell (3) and a member (5) forming a switch. The electrochemical cell comprises a chamber (31), two electrodes (33; 35), each being arranged at least in part in the chamber, and an electrolyte (37) contained in the chamber between the two electrodes. The composition and the structure of each of the two electrodes and of the electrolyte are selected conjointly in such a way that: - each of the electrodes is chemically inert in the electrolyte, and - in the absence of external polarisation, the electrodes have a non-zero difference in potential with respect to each other. The member forming a switch is electrically connected between the two electrodes. The member is arranged to switch alternately between an open state and a closed state by means of an external energy.

Classes IPC  ?

• H01G 11/04 - Condensateurs hybrides
• H01G 11/08 - Combinaisons structurelles, p. ex. assemblage ou connexion de condensateurs hybrides ou EDL avec d’autres composants électriques, au moins un condensateur hybride ou EDL étant le composant principal
• H01G 11/14 - Agencements ou procédés de réglage ou de protection des condensateurs hybrides ou EDL
• H01G 11/74 - Bornes, p. ex. extensions des collecteurs de courant
• H01M 12/00 - Éléments hybridesLeur fabrication
• H01G 11/82 - Fixation ou assemblage d’un élément capacitif dans un boîtier, p. ex. montage d’électrodes, de collecteurs de courant ou de bornes dans des récipients ou des encapsulations

Abrégé

The present application describes a process for the preparation of titanium-based compounds having an anatase type structure with cationic vacancies arising from a partial substitution of oxygen atoms by fluorine atoms and hydroxyl groups. Electrochemically active materials comprising the titanium-based compounds for use in lithium-ion battery electrodes are also described.

Classes IPC  ?

• H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
• C30B 7/14 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses le matériau à cristalliser étant produit dans la solution par des réactions chimiques
• C30B 29/16 - Oxydes
• H01M 4/1315 - Électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx contenant des atomes d'halogène, p. ex. LiCoOxFy
• C30B 29/10 - Composés inorganiques ou compositions inorganiques
• C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
• C01G 23/00 - Composés du titane
• C30B 29/64 - Cristaux plats, p. ex. plaques, bandes ou pastilles
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/052 - Accumulateurs au lithium

Abrégé

The present invention pertains to the field of nanoimprint lithography (NIL) processes and more specifically to a soft NIL process used for providing a sol-gel patterned layer on a substrate. Specifically, this process comprises a step of adjusting the solvent uptake of the sol- gel film to 10 to 50% vol., preferably between 15 and 40% vol., by varying the relative pressure of the solvent while a soft mould is applied onto the substrate coated with the sol-gel film.

Classes IPC  ?

• G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet

Abrégé

The invention relates to a method for obtaining a numerical model, the numerical model associating at least one objective measurement to a subjective sensation, the method comprising the steps of: a) imaging the at least one area of the brain by using unfocused waves produced by a transcranial ultrasound probe (20), to obtain at least one acquired image of the activity of the area, b) evaluating a physical quantity representative of the activity of the at least one area based on the acquired images, to obtain at least one objective measurement, c) obtaining from the subject at least one numerical value representative of a subjective sensation, and d) determining the numerical model by using the obtained objective measurement and the obtained numerical value.

Classes IPC  ?

• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine
• A61B 8/08 - Applications cliniques
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• A61B 8/06 - Mesure du débit sanguin
• G06T 7/00 - Analyse d'image

Abrégé

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

Classes IPC  ?

• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• C12R 1/225 - Lactobacillus
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to a method for designing a flexible blade or an articulated rigid blade with one or more torsion springs, for a wind turbine or a water turbine, the flexible blade being designed to passively control the pitch angle of the wind turbine or of the water turbine during operation, the method comprising the following steps: a) receiving the known geometric profile; b) determining a change in the optimal pitch angle, 0o opt rigid, as a function of the specific speed λ; c) determining the local behaviour of the flexible blade or of the articulated blade and local ratios relating to the aerodynamic loading and to the centrifugal force being exerted on the blade; d) determining local values of the bending modulus B of the flexible blade/the stiffness of the torsion spring and of the mass density p of the blade; and e) providing information relating to the selection of the material.

Classes IPC  ?

• F03D 1/06 - Rotors

Abrégé

The invention relates to a process for permanently electrostatically doping a layer of a conductive or non-conductive material that is deposited on a solid substrate, to the doped material obtained according to this process, and to the use of such a material.

Classes IPC  ?

• C03C 17/245 - Oxydes par dépôt à partir d'une phase vapeur
• C03C 17/22 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par d'autres matières inorganiques
• C03C 17/23 - Oxydes
• H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
• H01L 31/028 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des éléments du groupe IV de la classification périodique
• H01L 31/032 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés non couverts par les groupes
• H01L 31/0224 - Electrodes
• H01B 13/00 - Appareils ou procédés spécialement adaptés à la fabrication de conducteurs ou câbles
• H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par  ou de leurs parties constitutives

Abrégé

Intraocular injection of adeno-associated viral (AAV) vectors has been an evident route for delivering gene drugs into the retina. Currently, the vectors need to be injected into the subretinal space in order to provide gene delivery to cones. In this approach, gene delivery is limited to cells that contact the local "bleb" of injected fluid. Furthermore, retinal detachment that occurs during subretinal injections is a concern in eyes with retinal degeneration. Here, the inventors establish several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea with supporting studies in mouse models, human induced pluripotent stem cell-derived organoids, post-mortem human retinal explants and living macaques. They show that an engineered AAV2 variant provides gene delivery to foveal cones with a well-tolerated dose administered intravitreally. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Accordingly, the present invention relates to method of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising intravitreal delivery of a therapeutically effective amount of a recombinant AAV2-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 1 and the polynucleotide of interest under the control of the PR1.7 promoter as set forth in SEQ ID NO:2.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
• C12N 15/86 - Vecteurs viraux

Abrégé

Disclosed is a fluidic device including at least: a) a solid matrix; b) a textile component, embedded in the matrix and mechanically cohesive with the matrix; c) at least one channel embedded in the matrix and entangled with the textile component, the channel being at least partly open. A method for making a fluidic device includes providing a textile component including support fibers and at least a movable fiber entangled with the textile, embedding at least part of the textile and part of the movable fiber, in a matrix precursor material, applying a treatment in order to obtain a solid matrix.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• B32B 7/00 - Produits stratifiés caractérisés par la relation entre les couchesProduits stratifiés caractérisés par l’orientation relative des éléments caractéristiques entre les couches, ou par les valeurs relatives d’un paramètre mesurable entre les couches, c.-à-d. produits comprenant des couches ayant des propriétés physiques, chimiques ou physicochimiques différentes Produits stratifiés caractérisés par la jonction entre les couches
• D03D 11/02 - Tissus comportant des poches, tubes, boucles, plis, plissés ou rabats
• F16K 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
• D03D 15/06 - Tissus caractérisés par la matière ou la structure du fil ou des autres éléments utilisés en chaîne ou en trame utilisant des fils de soutien, c. à d. des fils qui sont éliminés après le tissage
• D06M 15/15 - Protéines ou leurs dérivés
• D06M 15/643 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone contenant du silicium dans la chaîne principale
• F16L 11/08 - Manches, c.-à-d. tuyaux flexibles en caoutchouc ou en matériaux plastiques flexibles avec armature noyée dans la paroi
• B29C 70/02 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant des combinaisons de renforcements et de matières de remplissage dans une matrice, formant une ou plusieurs couches, avec ou sans couches non renforcées ou non remplies
• B29C 70/22 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement caractérisées par la structure des renforcements fibreux utilisant des fibres de grande longueur, ou des fibres continues orientées dans au moins deux directions formant une structure bidimensionnelle
• D03D 13/00 - Tissus caractérisés par la disposition particulière des fils de chaîne ou de trame, p. ex. avec fils de trame incurvés, avec fils de chaîne discontinus, avec fils de chaîne ou de trame en diagonale
• B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
• B32B 3/20 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche discontinue, c.-à-d. soit continue et percée de trous, soit réellement constituée d'éléments individuels caractérisés par une couche interne formée d'éléments individuels de pièces creuses, p. ex. de tubesProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche discontinue, c.-à-d. soit continue et percée de trous, soit réellement constituée d'éléments individuels caractérisés par une couche interne formée d'éléments individuels de pièces comportant des rainures ou des cavités
• B32B 5/26 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par la présence de plusieurs couches qui comportent des fibres, filaments, grains ou poudre, ou qui sont sous forme de mousse ou essentiellement poreuses une des couches étant fibreuse ou filamenteuse un autre couche également étant fibreuse ou filamenteuse
• B32B 5/14 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par une couche différant en certains endroits du fait de sa constitution ou de sa structure physique, p. ex. plus dense superficiellement
• B32B 3/08 - Caractérisés par des caractéristiques de forme en des endroits déterminés, p. ex. au voisinage des bords caractérisés par des éléments ajoutés à des endroits déterminés
• B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
• D06M 101/06 - Fibres végétales cellulosiques

Abrégé

Disclosed is a minifluidic device including a matrix, an elongated guiding duct embedded at least in part in the matrix, with at least one port to the outside of the matrix, a movable fiber at least partly contained in the guiding duct, and able to undergo within the guiding duct, and at least along some part of the fiber, at least one action selected among a sliding, or a deformation, or a rotation and at least one of the movable fiber or the guiding duct is elastic or is non linear along at least part of its length, or at least part of the matrix is elastic.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• F16K 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe

Abrégé

The invention relates to a method and system for managing data exchanges in a communications network, comprising a centralised entity (20) that is provided, at least, with knowledge of the data exchange requirements between the terminals Mi (21) and their location in the network, in order to control the exchange of messages between the terminals.

Classes IPC  ?

• H04W 4/02 - Services utilisant des informations de localisation
• G06F 17/30 - Recherche documentaire; Structures de bases de données à cet effet
• H04W 76/00 - Gestion de la connexion

Abrégé

The invention relates to a control method for a multi-core processor comprising a plurality of cores (10) sharing at least one common material resource (12) according to a sharing policy based on different time windows (F), each time window (F) being attributed to at least one core (10). The control method comprises the anticipation of a request to be emitted by a software application (AP) run by a core (10) and requiring a transaction between said core (10) and the common resource (12), the planning of the transaction in a time window (F) to be attributed to said core (10) for access to the common resource (12), the implementation of the planned transaction and the loading of the data into a private cache memory (16) of said core (10), and the restitution of the data to the software application (AP) from the private cache memory (16).

Classes IPC  ?

• G06F 9/52 - Synchronisation de programmesExclusion mutuelle, p. ex. au moyen de sémaphores

Abrégé

The present invention relates to methods of predicting the survival time of patients suffering from CMS3 colorectal cancer. The inventors performed bivariate Cox models for analyzing the impact of stimulatory/Inhibitory immune checkpoint (ICK) expression on the survival of patients suffering from colorectal cancers (CMS1, CMS2, CMS3, CMS4, and MSI) in 2 cohorts (CIT and TCGA) or when the corhorts are combined. The inventors demonstrated that the expression of stimulatory ICK metagene was associated with good prognosis in CMS3. Thus, the present invention relates to a method of predicting the survival time of a patient suffering from a CMS3 colorectal cancer comprising i) determining the expression level of at least one immune stimulatory checkpoint molecule in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the patient will have a long survival time when the level determined at step i) is higher than the predetermined reference value or concluding that the patient will have a short survival time when the level determined at step i) is lower than the predetermined reference value.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer. The inventors performed bivariate Cox models for analyzing the impact of stimulatory/Inhibitory immune checkpoint (ICK) expression on the survival of patients suffering from colorectal cancers (CMS1, CMS2, CMS3, CMS4, and MSI) in 2 cohorts (CIT and TCGA) or when the corhorts are combined. The inventors demonstrated that the metagenes corresponding to ICKs, cytotoxic T-cell lymphocytes (CTL), cytotoxicity and Th1 orientation were overexpressed in MSS tumors belonging to CMS1 and CMS4 as compared to MSS CRC from CMS2 and CMS3 demonstrating their prognostic value. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a microsatellite stable colorectal cancer belonging to consensus molecular subtypes CMS1 and CMS4 comprising i) determining the expression level of at least one gene encoding for an immune checkpoint protein in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the patient will have a long survival time when the level determined at step i) is lower than the predetermined reference value or concluding that the patient will have a short survival time when the level determined at step i) is higher than the predetermined reference value.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

According to one aspect, the present description concerns a THz laser source (10) comprising a first generator (1) suitable for emitting at least a first light radiation (i) and a second light radiation (ii) having frequencies that are multiples of a first reference frequency; a second generator (2) suitable for emitting at least a first light radiation (iii) and a second light radiation (iv) having frequencies that are multiples of a second reference frequency different from the first reference frequency; the THz laser source also comprises a non-linear crystal (3) suitable for forming, from said first light radiations emitted by each of the first and second generators, a THz light radiation (v) generated by frequency difference, having frequency between 0.3 THz and 10 THz; and at least a first frequency stabilisation module for frequency stabilisation of one of said second radiations emitted by one of the first and second generators on an atomic transition.

Classes IPC  ?

• G02F 1/35 - Optique non linéaire
• H01S 3/13 - Stabilisation de paramètres de sortie de laser, p. ex. fréquence ou amplitude
• H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet

Abrégé

The invention relates to a sol-gel method for producing an anti-corrosion coating consisting of at least one layer (31, 32) of an oxide on a metal substrate (10). A non-aqueous solution (1) of a precursor of the oxide is prepared (SI) and deposited (S2) on one surface (11) at least of the metal substrate in order to cover said surface at least partially with a film (20) comprising the precursor of the oxide. Hydrolysis-condensation of the precursor of the oxide is carried out (S3) by exposing the film to a humid atmosphere in order to form an oxide network in the film. Then, a treatment for stabilising the film on the surface of the substrate is carried out (S4), followed by a heat treatment (S5) of the surface of the metal substrate in order to crystallise the network of oxide and form the anti-corrosion coating.

Classes IPC  ?

• C23C 18/12 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtementDépôt par contact par décomposition thermique caractérisée par le dépôt sur des matériaux inorganiques, autres que des matériaux métalliques

Abrégé

The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The sensory substitution system comprises a portable matrix of exciters (1) that can be worn by a user in such a way that the exciters (5) are placed against the skin of a user, as well as a control circuit (8) for the exciters of the matrix. An asynchronous signal source (10) provides the control circuit with an asynchronous signal representative of visual information organized according to a matrix of pixels. This asynchronous signal comprises, for each pixel, successive events associated in an asynchronous manner with said pixel.

Classes IPC  ?

• A61F 9/08 - Dispositifs ou méthodes permettant au patient de voir en remplaçant la perception directe de la vue par une autre
• G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
• G06K 9/46 - Extraction d'éléments ou de caractéristiques de l'image

Abrégé

The present invention relates to a piezosensitive coating (12) for detecting impacts (121, 122, 123, 124) on a substrate (10), comprising a matrix in which at least one piezochromic pigment is dispersed, said matrix being a hybrid sol-gel/polymer matrix composed of at least one organic precursor and one inorganic precursor that are polymerised, the piezochromic pigment being selected such that said coating changes colour as from a predetermined pressure threshold that corresponds to a transition pressure at which the piezochromic pigment in the matrix changes between two polymorphic forms of different colours. The invention further relates to a method for producing- such a piezosensitive coating.

Classes IPC  ?

• C09D 5/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, caractérisées par leur nature physique ou par les effets produitsApprêts en pâte
• C09K 9/00 - Substances devenant sombres, c.-à-d. substances pour lesquelles la gamme de longueurs d'onde absorbées est modifiée par excitation avec une énergie sous une forme quelconque
• C08K 3/22 - OxydesHydroxydes de métaux
• C09D 7/61 - Adjuvants non macromoléculaires inorganiques

Abrégé

The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 27/02 - Agents ophtalmiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

Device (100) for holding in position a probe for placing the inside of a patient's body in communication with the outside, characterized in that it comprises, arranged along a longitudinal axis (X-X′) of the device: at its distal end, a means (110) of supporting the device on the patient's body and that extends radially, comprising an axial opening (114) for the passage of said probe and comprising a first radial opening (111) communicating with the said axial opening, at its proximal end, a means (120) of guiding said probe comprising a second radial opening (121), a means (130) of spacing said bearing means and said guide means apart longitudinally.

Classes IPC  ?

• A61M 25/02 - Dispositifs de maintien en position, p. ex. sur le corps
• A61M 16/04 - Tubes trachéaux

Abrégé

The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of retinal degenerative diseases. The inventors identified a new key actor of the mechanism underlying the protective role of RdCVF: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2). The inventors showed that PFKFB2 is expressed by cones in a rod-dependant manner. In particular, they showed that its expression follows the viability of cones: its expression is lost in an animal model retinitis pigmentosa. The inventors accumulated evidences that PFKFB2, especially its kinase domain, is involved in the mechanism of action of RdCVF. More particularly they showed that transduction of a polynucleotide encoding for PFKFB2 increases cone survival. In particular, the present invention relates to a method of treating a retinal degenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding for the PFKFB2 kinase domain.

Classes IPC  ?

• A61K 38/45 - Transférases (2)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/861 - Vecteurs adénoviraux
• A61P 27/02 - Agents ophtalmiques

Abrégé

2 powders, of nanometric or micrometric size.

Classes IPC  ?

• C01B 25/08 - Autres phosphures
• C01B 35/10 - Composés contenant du bore et de l'oxygène

Abrégé

Method implemented by computer for simulating an optical system (102) comprising the steps consisting in: a) defining a set of light rays or beams at the input (e) of the optical system, each said light ray or beam being represented by a first vector of parameters (101, x e ); and b) calculating, for each said light ray or beam at the input of the optical system, a light ray or beams at the output (s) of the optical system, represented by a second vector of parameters (103, xs) by applying, to each said light ray or beam at the input of the optical system, one and the same nonlinear function, termed the transmission function (I), representative of the optical system as a whole. Computer program product for the implementation of such a method.

Classes IPC  ?

• G06F 17/18 - Opérations mathématiques complexes pour l'évaluation de données statistiques
• G02C 7/02 - VerresSystèmes de verres

Abrégé

The present invention concerns the isolation, purification and characterisation of a protein having a novel enzymatic activity, i.e. an alpha-1,3-(3,6-anhydro)-D-galactosidase activity. This protein can be used for hydrolysing polysaccharides and oligosaccharides containing (non-sulfated) beta-carrabiose units, which may be present naturally (e.g. carrageenans extracted from red seaweeds of the Tichocarpus and Furcellaria genus) or introduced artificially by chemical or enzymatic desulfation (for example from kappa- and iota-carrageenans). The activity of this protein, demonstrated on oligo-carrageenans with a hybrid kappa/beta structure, makes it possible, for example, to produce the 3,6-anhydro-D-galactose monosaccharide and odd-numbered oligo-carrageenans of a defined size of the carrabiose series, i.e. having a D-galactose residue at the non-reducing end.

Classes IPC  ?

• A01H 13/00 - Algues
• A61K 8/73 - Polysaccharides
• A61K 31/731 - Carraghénanes
• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

The invention relates to a portable device (1) for estimating at least one characteristic parameter of a polymer, characterized in that the device includes: at least one infrared source (101), each infrared source (101) being able to emit, toward the polymer, a spectral line, representing a maximum emission energy, of wavelength chosen from 10 μm, 9.5 μm, 7.2 μm, 6 μm, 3.5 μm and 2.7 μm, or of wave number chosen from 1000 cm-1, 1050 cm-1, 1350 cm-1, 1700 cm-1, 2900 cm-1 and 3700 cm-1; at least one infrared detector (102) that is able to receive the infrared radiation (112) reflected by the polymer (M) in response to the spectral line; and a unit for determining the characteristic parameter of the polymer (M) depending on the energy present in said spectral line in the infrared radiation (112) reflected by the polymer (M) and received by the infrared detector (102).

Classes IPC  ?

• G01N 21/3563 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de solidesPréparation des échantillons à cet effet
• G01N 21/55 - Réflexion spéculaire
• G01N 21/84 - Systèmes spécialement adaptés à des applications particulières

Abrégé

The present invention relates to a process for characterizing a blood sample, comprising: insertion, into a channel, of a solution comprising blood platelets, said channel comprising an inlet and an outlet, the solution being inserted via the inlet of the channel; creating a pressure difference between the inlet and the outlet of the channel so as to cause the solution to progress from the inlet towards the outlet of the channel; passage of the solution into a measurement zone of the channel, provided with electrodes; measurement, by said electrodes and measurement means, of an electric signal while said electrodes are covered by the solution in the channel, characterized in that the progression of the solution from the inlet towards the outlet of the channel comprises a progression of a front between, on the one hand, the solution extending from the front towards the inlet of the channel and, on the other hand, a gas extending from the front towards the outlet of the channel.

Classes IPC  ?

• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

The invention relates to a bioreactor comprising a tank containing a culture medium in which a cell culture composed of algae cells is dispersed. The cell culture of algae has a concentration greater than 0.1 g/L in the culture medium, and each algal cell has a minimum absorption in a specific range of wavelengths of light. The bioreactor comprises a light source that is capable of emitting incident light in the direction of the tank, 60% of the photons of the incident light having a wavelength which is included in said specific range of wavelengths of light. The invention also relates to the use of the bioreactor for the production of biomass.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie

Abrégé

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I)for organs preservation.

Classes IPC  ?

• C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
• C07D 311/54 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre en positions 2 et 4 avec un atome d'hydrogène en position 3 substitués dans le carbocycle
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine

Abrégé

The invention relates to a piezoelectric transducer of the type comprising a stack of a contact part (1), of a piezoelectric chip (2) and of a holder (3) of very high stiffness. Specifically, the contact part (1) forms tips, the respective apex of which forms points of contact that are spatially isolated from one another. The invention also relates to a process for manufacturing such a contact part and to a resonant ultrasound spectroscopy device comprising one or more piezoelectric transducers according to the invention.

Classes IPC  ?

• G01N 29/036 - Analyse de fluides en mesurant la fréquence ou la résonance des ondes acoustiques
• G01H 13/00 - Mesure de la fréquence de résonance
• G01N 29/04 - Analyse de solides
• G01N 29/22 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet Détails
• G01N 29/24 - Sondes
• G01N 29/28 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet Détails pour établir le couplage acoustique
• G10K 11/24 - Procédés ou dispositifs pour transmettre, conduire ou diriger le son pour conduire le son à travers des corps solides, p. ex. fils métalliques

Abrégé

The invention relates to a supercapacitor comprising: an electrolyte having a first end and a second end opposite the first end; a first electrode (E1) in contact with the first end of the electrolyte; and a second electrode (E2) in contact with the second end of the electrolyte. In particular, the electrolyte is made from an ionically conductive and electronically insulating solid material (D).

Classes IPC  ?

• G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
• H01L 45/00 - Dispositifs à l'état solide spécialement adaptés pour le redressement, l'amplification, la production d'oscillations ou la commutation, sans barrière de potentiel ni barrière de surface, p.ex. triodes diélectriques; Dispositifs à effet Ovshinsky; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
• H01G 11/56 - Électrolytes solides, p. ex. gelsAdditifs pour ceux-ci
• H01G 11/84 - Procédés de fabrication de condensateurs hybrides ou EDL ou de leurs composants
• H01G 11/14 - Agencements ou procédés de réglage ou de protection des condensateurs hybrides ou EDL
• G11C 13/02 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou utilisant des éléments dont le fonctionnement dépend d'un changement chimique
• C04B 35/465 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base d'oxydes de titane ou de titanates à base de titanates à base de titanates de métaux alcalino-terreux

Abrégé

The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.

Classes IPC  ?

• A61B 8/06 - Mesure du débit sanguin
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation
• A61B 8/08 - Applications cliniques

Abrégé

By analyzing the kinetics of the immunological parameters evocating the immune risk phenotype (IRP) in elderly subjects suffering from an acute event, the inventors have surprisingly identified that neopterin expressed highly in the subjects who has a short survival time after an acute event. Accordingly, the invention relates to a method for predicting the survival time in a subject suffering from an acute event comprising the following steps: i) determining neopterin level in a biological sample obtained from said subject; ii) comparing said level with its predetermined reference value and iii) concluding that the subject will have a short survival time when the level of neopterin is higher than its predetermined reference value or concluding that the subject will have a long survival time when the level of neopterin is lower than its predetermined reference value.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention relates to variants of acid-alpha glucosidase and uses thereof. Said variants are sequence-optimized and/or are linked to a heterogenous signal peptide.

Classes IPC  ?

• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase

Abrégé

The present invention relates to variants of acid-alpha glucosidase and uses thereof.

Classes IPC  ?

• C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs

Abrégé

Disclosed is the preparation of injectable collagen suspensions, to the method for preparing the suspensions, and to the uses thereof, particularly for forming dense collagen matrices.

Classes IPC  ?

• A61L 27/24 - Collagène
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61L 27/52 - Hydrogels ou hydrocolloïdes
• A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
• A61K 8/14 - Liposomes
• A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
• A61K 8/65 - CollagèneGélatineKératineLeurs dérivés ou produits de dégradation
• A61Q 19/08 - Préparations contre le vieillissement
• A61K 8/60 - SucresLeurs dérivés
• C08J 3/12 - Pulvérisation ou granulation

Abrégé

An autonomous vehicle having a chassis and supporting legs, each of said legs being composed of at least two segments, an upper segment connected to the chassis via a first pivot, and a lower segment carrying a wheel at its lower end and connected to the upper segment by a second pivot; in addition, the lower segment is connected, via two opposing springs, to a pulley rigidly secured to the chassis in order to generate an angular rigidity about an equilibrium position corresponding to an upright orientation of the lower segment; and the upper segment is connected via two other opposing springs, at said first pivot, to a motorised pulley rigidly secured to the chassis and suitable for controlling the moment exerted on the upper segment about a nominal position corresponding to a horizontal orientation of the upper segment, this moment control being determined on the basis of a measurement of a first angle formed by the upper segment relative to its nominal position, a measurement of a second angle formed by the lower segment relative to its equilibrium position, and the trim of the chassis.

Classes IPC  ?

• B60K 17/32 - Agencement ou montage des transmissions sur les véhicules les éléments propulsifs terminaux, p. ex. les roues, étant basculantes autour d'un pivot horizontal

Abrégé

An interstitial ultrasound thermal ablation applicator for conformal treatment of an inhomogeneous tumor lesion includes: a body having a longitudinal axis; and a plurality of array transducers mounted on the body, arranged side by side and having azimuth directions parallel to the longitudinal axis of the body, and having outer faces disposed in a polygonal arrangement; the plurality of array transducers having predetermined elevation dimensions defined for directing emitted ultrasonic energy to obtain a conformal volume treatment of the tumor lesions. An electronic driving method for driving an applicator having multiple independent transducer elements arranged in rows and columns includes: controlling focal parameters of each row and column of transducer elements; and controlling a contribution of each row and column of transducer elements in a manner to provide a conformal ablated volume.

Classes IPC  ?

• A61N 7/02 - Hyperthermie localisée par ultrasons
• A61N 7/00 - Thérapie par ultrasons

Abrégé

The present invention relates to methods for quantifying the population of myeloid dendritic cells in a tissue sample. The tumor microenvironment is a complex tissue which contains many distinct cell populations, and whose composition may predict prognosis and response to therapies. In the present disclosure, using samples of purified cell populations, the inventors defined specific and robust transcriptomic markers of the immune and stromal cell populations of the tumor microenvironment, and they quantitatively validated them in an in-vitro RNA mixture model. More, they developed the 'Microenvironment Cell Populations-counter' (MCP-counter) method, which, using transcriptomic data, allows a robust quantification of the abundance of immune and stromal populations in cellularly heterogeneous healthy and cancerous tissues. Thus, the present invention relates to a method for quantifying the population of myeloid dendritic cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CD1E, CLEC10A, CLIC2, CD1A, WFDC21P and CD1B.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a method for routing a plurality of data streams in a wireless communication network (R) comprising a plurality of nodes connected by wireless communication links, the method comprising the steps of: identifying (101) at least one group of wireless communication links of the network which would all interfere with each other if they were used simultaneously to transmit data, determining (102), for each data stream, a path in the network for transmitting the data stream, each path being characterised by a set of nodes of the network, the determination comprising solving a system of equations of which the paths are solutions, the system of equations defining the following rules: the total number of nodes to include in the paths is to be minimised; for each identified group, the rate of use in capacity of the group, by the plurality of data streams, must be less than or equal to a predetermined threshold; each stream is to be transmitted from a predetermined source node of the network to a predetermined recipient node of the network; each node not being a recipient and receiving a stream must retransmit this stream to a single other node; the method further comprising a deactivation (103) of at least one node of the network which is not included in at least one of the determined paths.

Classes IPC  ?

• H04L 12/729 - Sélection d’un chemin avec bande passante ou débit adéquat
• H04W 40/16 - Sélection d'itinéraire ou de voie de communication, p. ex. routage basé sur l'énergie disponible ou le chemin le plus court sur la base de la qualité d'émission ou de la qualité des canaux sur la base des interférences
• H04L 12/721 - Procédures de routage, p.ex. routage par le chemin le plus court, routage par la source, routage à état de lien ou routage par vecteur de distance

Abrégé

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61K 31/382 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à six chaînons, p. ex. thioxanthènes
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/12 - Antiviraux
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès

Abrégé

The invention relates to a device (3) for detecting a blood alcohol level, comprising: - a flexible strip (1) intended to be exposed to an atmosphere to be tested (4), particularly one optionally filled with ethanol and more particularly with a person's exhaled breath, the flexible strip (1) comprising a flexible substrate (5) and a hydrophobic porous layer (7) arranged on the flexible substrate (5) and having a surface area of accessible pores of the porous layer (7) arranged on the flexible substrate (5) greater than 140cm2/cm2, the flexible substrate (5) being prestressed so that, in the absence of ethanol, the flexible strip (1) has an initial curvature and in the presence of ethanol the flexible strip (1) has a lower curvature, - a detector (21) of variation of the curvature of the flexible strip (1) and - a processing and calculating unit (23) configured for deducing, from the measured variation of the curvature of the flexible strip (1), a parameter corresponding to a blood alcohol level.

Classes IPC  ?

• G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p. ex. de l'haleine

Abrégé

The invention relates to a pumped-down optical apparatus (1) including a vacuum chamber (2), the vacuum chamber including walls bounding a sealably closed interior space (5), wherein an internal surface of the walls (3, 4) includes a layer of oxidized metal alloy, the metal alloy including at least one metal chosen from the list consisting of: titanium, copper, steel and aluminium, the pumped-down optical apparatus furthermore including a porthole able to transmit a laser beam (10, 11) emitted by an optical source (7, 8) at a wavelength of the optical source, the oxidized metal alloy being able to absorb the wavelength of the optical source (7, 8) so that the total reflectivity of the internal surface of the wall (3, 4) is lower than 0.5 for the wavelength of the optical source. The invention also relates to a method for obtaining the pumped-down optical apparatus.

Classes IPC  ?

• G01C 19/64 - Gyromètres utilisant l'effet Sagnac, c.-à-d. des décalages induits par rotation de faisceaux électromagnétiques dans des directions opposées
• B01J 3/03 - Récipients sous pression, ou récipients sous vide, comportant des organes de fermeture ou des joints d'étanchéité spécialement adaptés à cet effet
• H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitementAppareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
• G01V 7/00 - Mesure de champs ou d'ondes de gravitationProspection ou détection gravimétrique
• G04F 5/14 - Appareils pour la production d'intervalles de temps prédéterminés, utilisés comme étalons utilisant des horloges atomiques
• B01J 3/00 - Procédés utilisant une pression supérieure ou inférieure à la pression atmosphérique pour obtenir des modifications chimiques ou physiques de la matièreAppareils à cet effet
• C23C 8/10 - Oxydation

Abrégé

The present invention relates to an electrode comprising an electrically conductive substrate of which at least one portion of the surface is covered with a metal deposit of copper, the surface of said deposit being in an oxidised, sulphurised, selenised and/or tellurised form and the deposit having a specific surface area of more than 1 m2/g; a method for preparing such an electrode; and a method for oxygenising water with dioxygen involving such an electrode.

Classes IPC  ?

• C25B 11/04 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par le matériau
• C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
• C25D 7/00 - Dépôt électrochimique caractérisé par l'objet à revêtir
• H01M 4/88 - Procédés de fabrication

Abrégé

The invention relates to a new method for the prevention and treatment of wave burst arrhythmia by administering a gestagen having an androgenic effect.

Classes IPC  ?

• A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
• A61K 31/5685 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone ayant un groupe oxo en position 17, p. ex. androstérone
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
• A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
• A61K 31/567 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en position 17 alpha, p. ex. mestranol, noréthandrolone

Abrégé

A method and a device allow optical properties of a sample to be estimated. The method includes the illumination of the sample by a first light source, and the formation of an image of the sample thus illuminated, on the basis of which a first optical property is estimated, at various points on a surface of the sample. The method also includes measuring an auxiliary optical property of the sample and estimating the first optical property, taking account of the auxiliary optical property measured on the sample.

Classes IPC  ?

• G01N 21/55 - Réflexion spéculaire
• G01N 21/47 - Dispersion, c.-à-d. réflexion diffuse
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present invention relates to the field of cardiology and, more specifically, to a novel algorithm that can be used, in particular, in a method for determining if a drug is likely to induce a cardiac ventricular repolarisation disturbance, based on variations in electrocardiogram data.

Classes IPC  ?

• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/04 - Mesure de signaux bioélectriques du corps ou de parties de celui-ci
• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales

Abrégé

The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.

Classes IPC  ?

• A61N 7/00 - Thérapie par ultrasons
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine

Produits et services

Software for making medical diagnoses, developing treatment plans, monitoring, checking and simulating patient care, managing and transmitting patient data, information and digital images and testing medical apparatus; search software (recorded programs) in the field of medical imaging; software (recorded programs) for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); surgery monitoring software (recorded programs); medical and surgery management software (recorded programs); software for recording, storing, analyzing, transmitting, operating, managing and processing medical data; tools (software and recorded programs) for developing software for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); apparatus for recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); scientific, optical and medical checking (supervision) apparatus and instruments; apparatus and equipment for recording, transmitting, reproducing medical images and/or sound; apparatus and equipment for processing data, computers and computer peripherals for use in medical imaging; scientific instruments and application software in the field of medicine and biology to assist with prevention, diagnostics and therapy; image processing apparatus for medical imaging and visualization and related displays. Installation, maintenance and repair of software, equipment and computer systems and medical systems and apparatus. Design and development of computer systems for scientific and medical imaging and medical data management; technical project studies in the field of medical data and surgical and medical imaging; new product development and research for others in the field of medical imaging, visualization and medical data management; new product development and research for others with respect to recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); design of computer systems to enable the simulation of physiological systems based on computer models using biomedical images and other signals; analyses, evaluations, appraisals and research in scientific and technological fields carried out by engineers; development, design, installation, maintenance, updating or rental of medical imaging and medical data mining software; computer programming, consultancy relating to computers and medical imaging and medical data mining software; technical support (consulting) relating to medical imaging and medical data mining software; conversion of data and computer programs (other than physical conversion) relating to medical imaging and medical data mining; conversion of data or documents from physical to electronic media relating to medical imaging and medical data mining; scientific research for medical purposes; expert activities relating to medical imaging and medical data mining carried out by engineers; engineering services relating to medical imaging and medical data mining; scientific studies and research relating to medical imaging and medical data mining; scientific studies and research on recording, storing, analyzing, transmitting, generating, displaying and processing medical data, medical images, signals (biological, physiological, physical, positional and audio); consultancy, studies and research relating to surgery, biology, chemistry, radiology, medical imaging; duplication of computer programs relating to medical imaging and medical data mining.

Abrégé

The invention concerns a hydrated titanium oxyhydroxide compound, a composite material comprising same and an electrode and a catalyst comprising said hydrated titanium oxyhydroxide compound and said composite material. The invention also concerns a battery, in particular a lithium battery, comprising said electrode. It further concerns a method for producing said hydrated titanium oxyhydroxide compound and said composite material. The hydrated titanium oxyhydroxide compound according to the invention has the following formula I; TiOx(OH)y, nH2O Formula 1 in which: - 1.15 ≤ x ≤ 1.55, and 0.9 ≤ y ≤ 1.70, and 0.1 ≤ n ≤ 1, preferably 0.3 ≤ n ≤ 0.5, and most preferably n = 0.41, and the compound has an ordered lepidocrocite local structure over a distance of up to 1 nm inclusive, as determined by analysis of the pair-distribution function (PDF) obtained by synchrotron diffraction, but has a disordered structure over a distance of more than 1 nm, revealed by X-ray diffraction. The invention is applicable in the field of energy storage and supply, in particular.

Classes IPC  ?

• B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
• C01G 23/04 - OxydesHydroxydes
• C01G 23/053 - Obtention par voie humide, p. ex. par hydrolyse de sels de titane
• H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy

Abrégé

The present invention concerns, in particular, a method for producing a catalyst intended to be incorporated into a catalytic converter system that can be used for treating an exhaust gas from a vehicle engine, said method comprising at least the following step: treating, by means of a gas phase, a structure comprising at least one zeolite, palladium and cerium, in order to obtain the catalyst, the gas phase comprising water vapour at a volume content of between 5% and 20% and a temperature of between 450 °C and 550 °C being imposed during said treatment.

Classes IPC  ?

• B01J 37/10 - Traitement thermique en présence d'eau, p. ex. de vapeur d'eau
• B01J 29/22 - Métaux nobles
• B01J 29/18 - Zéolites aluminosilicates cristallinesLeurs composés isomorphes du type mordénite
• B01D 53/94 - Épuration chimique ou biologique des gaz résiduaires des gaz d'échappement des moteurs à combustion par des procédés catalytiques
• F01N 3/28 - Structure des réacteurs catalytiques
• F01N 3/20 - Silencieux ou dispositifs d'échappement comportant des moyens pour purifier, rendre inoffensifs ou traiter les gaz d'échappement pour rendre les gaz d'échappement inoffensifs par conversion thermique ou catalytique des composants nocifs des gaz d'échappement caractérisés par les méthodes d'opérationCommande spécialement adaptés à la conversion catalytique

Abrégé

The invention concerns a method for managing a squad of mobile robotic vehicles, such as drones, each mobile robotic vehicle being configured to communicate and exchange information with other mobile robotic vehicles so that they constitute a network of mobile robotic vehicles and configured to communicate and exchange information with an operating center, said method comprising the following steps of: launching (Sl) a first mobile robotic vehicle (NO) which is the leader of the squad, the leader being configured to stay at a distance from an operating center (OC) for exchanging information with the operating center (OC) by ensuring that a quality of link (Q NO, OC ) of power exchanged between said first mobile robotic vehicle (NO) and said operating center (OC) is greater or equal to X dBm, the method comprising, if the quality of link (Q No - oc ) becomes lower than X dBm, launching (S4, S7) consecutively at least one mobile robotic vehicle (N1, N2,..., Nx) so that: each mobile robotic vehicle is configured to stay at distance from his closest neighbor(s) for exchanging information with his closest neighbor(s) by ensuring that a quality of link of power exchanged between said each mobile robotic vehicle and said closest neighbor(s) is greater or equal to X dBm; the last launched mobile robotic vehicle (Nx) is configured to stay at a distance from the operating center for exchanging information with the operating center by ensuring that a quality of link of power exchanged between said last mobile robotic vehicle and said operating center is greater or equal to X dBm.

Classes IPC  ?

• G05D 1/10 - Commande de la position ou du cap dans les trois dimensions simultanément
• H04L 12/26 - Dispositions de surveillance; Dispositions de test
• H04L 12/751 - Mise à jour ou découverte de la topologie
• H04L 12/24 - Dispositions pour la maintenance ou la gestion

Abrégé

The invention relates to ambient-temperature ferromagnetic cobalt nanoparticles, the production method thereof, a suspension of the nanoparticles, and the uses of said nanoparticles and said suspension, particularly in the field of high-density magnetic recording.

Classes IPC  ?

• B22F 1/00 - Poudres métalliquesTraitement des poudres métalliques, p. ex. en vue de faciliter leur mise en œuvre ou d'améliorer leurs propriétés
• B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p. ex. de solutions

Abrégé

The invention relates to the field of immunology and cell therapy. The invention relates to an in vitro or ex vivo method for obtaining hematopoietic cell population containing regulatory T cells (Tregs) specific for an irrelevant antigen, to a hematopoietic cell population obtained by said method, to a pharmaceutical composition and a product containing said hematopoietic cell population and therapeutic use thereof.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.

Classes IPC  ?

• C12N 15/861 - Vecteurs adénoviraux

Abrégé

The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.

Classes IPC  ?

• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The invention relates to a method and to a corresponding device for determining the slowness of propagation in a mode of propagation of an acoustic wave, including the following steps: a) transmitting an acoustic wave (OS) in a medium (M) using an acoustic source (SS); b) providing, with each sensor Tk of a set of n sensors (Tk, 1≤ k ≤ n, where n is an integer), the positions of which relative to one another and to the acoustic source are known, a transduction signal xk(t) that is dependent on the response time to the transmitted acoustic wave; c) carrying out, for slowness values s, a time shift τk(s) specific to each signal xk, i.e. xk(t+τk),k(t+τk), in order to reset in time said signals relative to each other; d) calculating interferometric signals C(t,s) on the basis of an estimator C which is a function of the quantity (I) or of the conjugate of said quantity, with xk = xk(t+τk) being a signal reset in time and x*k+j the conjugate of the signal xk+j = xk+j(t+τk+j); e) determining the slowness s0 of said propagation mode of the acoustic wave with one interferometric signal C(t,s) from the set of previously calculated interferometric signals C(t,s), said signal C(t,s) being selected on the basis of its complex argument and of its modulus.

Classes IPC  ?

• G01V 1/48 - Traitement des données

Abrégé

The present invention relates to a method for determining the presence or risk of developing thrombosis or the risk of a bleeding event in a patient, which method comprises determining presence or concentration of PDGFB in a biological sample of the patient, in a biological sample of the patient.

Classes IPC  ?

• G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

Abrégé

The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular, the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated viral (AAV) vector comprising a polynucleotide encoding for an interleukin 2 (IL-2) polypeptide.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to methods for quantifying the population of B cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of B cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of MS4A1, CD19, CD79A, FCRL2, CR2, PAX5, CD22, BANK1 and IGKC.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of cytotoxic lymphocytes in a tissue sample. In particular, the present invention relates to a method for quantifying the population of cytotoxic lymphocytes in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of KLRC4-KLRK1 /// KLRK1, CD8A, KLRD1, GNLY, EOMES, KLRC3, KLRC4, FGFBP2 and KLRC1 /// KLRC2.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of neutrophils in a tissue sample. In particular, the present invention relates to a method for quantifying the population of neutrophils in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CXCR2, VNN3, CYP4F3, HAL, GENE 1, FCGR3B, KCNJ15, CXCR1, STEAP4 and TNFRSF10C.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of NK cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of NK cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of KIR2DL1, KIR2DL3, NCR1, KIR3DL1, KIR3DS1, KIR3DL2, SH2D1B, CD160, GENE 2 and KIR2DL4.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of T cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of T cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of TRAT1, CD3D, THEMIS, ICOS, SIRPG, CD3G, CTLA4, CD6, CD5 and CD28.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of endothelial cells in a tissue sample. In particular, the present invention relates to a method for quantifying the population of endothelial cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CDH5, EMCN, MYCT1, ELTD1, ROBO4, CLEC14A, VWF, ESAM, MMRN2 and KDR.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention is within the field of human-machine interfaces. The invention relates to a haptic device capable of generating kinaesthetic feedback to a user of said device. According to the invention, the haptic device includes: a movable member (260), intended for being handled by a user; an actuator mechanism (220, 230, 240), arranged to remotely generate a mechanical stimulation force on the movable member; and a levitation mechanism, arranged to remotely generate a mechanical levitation force on the movable member, so as to keep the movable member in contactless equilibrium with respect to the levitation mechanism, the mechanical levitation force being orthogonal to the mechanical stimulation force.

Classes IPC  ?

• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
• G06F 3/0346 - Dispositifs de pointage déplacés ou positionnés par l'utilisateurLeurs accessoires avec détection de l’orientation ou du mouvement libre du dispositif dans un espace en trois dimensions [3D], p. ex. souris 3D, dispositifs de pointage à six degrés de liberté [6-DOF] utilisant des capteurs gyroscopiques, accéléromètres ou d’inclinaison

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of heart failure. In particular, the present invention relates to a method of treating heart failure in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a RCN-3 polypeptide or nucleic acid molecule encoding thereof.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque

Abrégé

The present invention relates to methods for quantifying the population of fibroblasts in a tissue sample. In particular, the present invention relates to a method for quantifying the population of fibroblasts in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of DCN, COL6A2, 10 COL6A1, COL3A1, COL1A1, PAMR1, TAGLN and GREM1.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to methods for quantifying the population of cells of monocytic origin in a tissue sample. In particular, the present invention relates to a method for quantifying the population of cells of monocytic origin in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CSF1R, ADAP2, RASSF4, FPR3, TFEC, PLA2G7 and KYNU.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a device (100) for treating a liquid by cavitation, which includes: a chamber capable of containing, while in use, a volume of liquid (50) to be treated; at least one first piston (200) mounted so as to slide sealingly in said chamber between a first position and a second position; and means (400) for driving the at least one first piston between said first and second positions. The device also comprises at least one second piston (300) mounted so as to slide sealingly in said chamber between a first position and a second position. The device is designed so that, when it contains liquid with a view to using same, one of the pistons is permanently in contact with the liquid and the other piston is separated from the free surface (51) of the liquid.

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
• C02F 1/34 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout au moyen d'oscillations mécaniques
• C02F 1/72 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation
• C02F 101/36 - Composés organiques contenant des atomes d'halogène

Abrégé

The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. The method is based on the precise determination of the localization of the replicating fork on the template by measuring the physical distance between one end of the molecule and the fork. This allows the determination of the physical location of the site where a pause or a blockage of the replication occurs, and deducing therefrom information on the sequence of the nucleic acid.

Classes IPC  ?

• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques

Abrégé

A compound of formula (I-1) 2-amine, R′1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

Classes IPC  ?

• C07D 311/02 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, condensés avec d'autres cycles condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques
• A61K 31/37 - Coumarines, p. ex. psoralène

Abrégé

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• C12R 1/01 - Bactéries ou actinomycètes
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• C12N 1/20 - BactériesLeurs milieux de culture
• A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis

Abrégé

The present invention relates to a force sensor (1), comprising: - at least one measurement cell (2), each measurement cell being filled with a filling material (3) in which is embedded at least one inclusion of matter (4), - for each cell, at least one light source (5) arranged so as to illuminate the inclusion embedded in this cell, - for each cell, a measurement system comprising at least one optical measurement point (7) arranged so as to sense the light originating from the inclusion embedded in this cell, for each cell, means (9, 10) arranged so as to transform optical signals (16) originating from the measurement system of this cell into a signal representative of a force (11) exerted on this cell, this signal depending on a displacement of the inclusion embedded within the filling material of this cell.

Classes IPC  ?

• G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
• G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p. ex. par l'analyse des contraintes par photo-élasticité

Abrégé

The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. In particular, the said method comprises the steps of denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence by applying a physical force to the said molecule; and detecting a blockage of the renaturation of the double-stranded nucleic acid molecule. More specifically, the method comprises the steps of denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence by applying a physical force to the said molecule; providing a single-stranded nucleic acid molecule; renaturing the said double stranded nucleic acid molecule in the presence of the said single-stranded nucleic acid molecule; and detecting a blockage of the renaturation of the double-stranded nucleic acid.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide

Abrégé

The invention relates to a method for giving a theme to a route taken by a vehicle, including steps of: receiving (21) an experience originating from a base of predefined experiences, said experience being associated with a plurality of milestones; receiving (22) a route originating from a navigation system of the vehicle; selecting (23), for each milestone of said experience, a place from a database of places, so that each of the places is associated with a milestone and is located in proximity to the route; receiving (24) geopositioning information originating from the navigation system, as the vehicle travels along the route, and indicating an actual position of the vehicle; and, when the geopositioning information coincides with a selected place, transmitting a signal ordering at least one medium associated with the selected place and the received experience to be broadcast (25) via an interface of the vehicle.

Classes IPC  ?

• G01C 21/36 - Dispositions d'entrée/sortie pour des calculateurs embarqués

Abrégé

The invention relates to a method for the permanent electrostatic doping of a layer of a conductive or non-conductive material deposited on a solid substrate, to the doped material produced according to said method, and to the use of such a material.

Classes IPC  ?

• C03C 17/22 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par d'autres matières inorganiques
• C03C 17/23 - Oxydes
• H01L 21/20 - Dépôt de matériaux semi-conducteurs sur un substrat, p. ex. croissance épitaxiale
• H01L 23/00 - Détails de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide

Abrégé

A fluidic device comprising at least: a/ a solid matrix (5), b/ a textile component (4), embedded in said matrix and mechanically cohesive with said matrix, c/ at least one channel (6) embedded in said matrix and entangled with said textile component (4), said channel (6) being at least partly open. A method for making a fluidic device comprising providing a textile component (4) comprising support fibers (1.1), (1.2) and at least a movable fiber (2) entangled with said textile (4), embedding at least part of said textile 4 and part of said movable fiber (2), in a matrix precursor material (5), applying a treatment in order to obtain a solid matrix (5).

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• B29C 67/00 - Techniques de façonnage non couvertes par les groupes , ou
• B29C 70/02 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant des combinaisons de renforcements et de matières de remplissage dans une matrice, formant une ou plusieurs couches, avec ou sans couches non renforcées ou non remplies
• F16L 11/08 - Manches, c.-à-d. tuyaux flexibles en caoutchouc ou en matériaux plastiques flexibles avec armature noyée dans la paroi
• B29C 67/20 - Techniques de façonnage non couvertes par les groupes , ou pour la fabrication d'objets poreux ou cellulaires, p. ex. des mousses plastiques, des mousses alvéolaires
• B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
• B32B 5/12 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments caractérisés par la disposition relative des fibres ou filaments des couches adjacentes
• B32B 17/04 - Produits stratifiés composés essentiellement d'une feuille de verre ou de fibres de verre, de scorie ou d'une substance similaire sous forme de fibres ou filaments collés ou enrobés dans une substance plastique
• D03D 11/02 - Tissus comportant des poches, tubes, boucles, plis, plissés ou rabats

Abrégé

A minifluidic device comprising a matrix, an elongated guiding duct (109) embedded at least in part in said matrix, with at least one port to the outside of the matrix, a movable fiber (104) at least partly contained in said guiding duct (109), and able to undergo within said guiding duct (109), and at least along some part of said fiber (104), at least one action selected among a sliding, or a deformation, or a rotation and at least one of the movable fiber or the guiding duct is elastic or is non linear along at least part of its length, or at least part of the matrix is elastic.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• F16K 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe

Abrégé

The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The invention is from the field of assistance in establishing a medical diagnosis and relates to a method for assisting in establish a diagnosis for a patient on the basis of at least one identified sign by relying on a computerized knowledge base comprising a medical ontology. The medical ontology includes: a list of signs, forming a "sign" class, a list of medical conditions, forming a "medical condition" class, and a first set of logical relationships between the signs and the medical conditions, each logical relationship establishing a correlative link between a sign and a medical condition. The method according to the invention includes: a step (503) of searching for medical conditions linked at least to one of the signs identified by means of the first set of logical relationships, and a step (504) of identifying potential signs, in which, for each potential medical condition, all the signs linked by a correlative link to said potential medical condition are identified by means of the first set of logical relationships.

Classes IPC  ?

• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire